Previous 10 | Next 10 |
Geron Corporation (NASDAQ: GERN) is one today's most active stocks by volume. So far today, approximately 40.37M shares of Geron Corporation have been exchanged, as compared to an average 30-day volume of 11.93M shares. Geron Corporation, a late-stage clinical biopharmaceutical company, focuse...
2024-03-15 10:06:29 ET More on Geron Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA Geron Corporation (GERN) Q4 2023 Earnings Call Transcript Geron wins FDA...
2024-03-15 10:00:13 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...
A look at the top 10 most actives in the United States Grab Holdings Limited (GRAB) fell 0.2% to $3.235 on volume of 103,635,000 shares Better Therapeutics Inc. (BTTX) rose 108.6% to $0.073 on volume of 98,804,254 shares Verb Technology Company Inc. (VERB) rose 156.3% to $0.3639 on volume...
2024-03-15 09:34:33 ET DENVER, Colo., Mar 15, 2024 ( 247marketnews.com )- Geron Corporation (NASDAQ: GERN ) announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat, based on results from the ...
2024-03-15 08:59:41 ET Summary Geron's valuation may overestimate imetelstat's market impact for MDS, given FDA's moderate enthusiasm and efficacy concerns. FDA concerns include imetelstat's marginal efficacy, safety issues, and a non-significant improvement in patient outcomes. ...
2024-03-15 05:45:23 ET More on related stocks: Adobe Inc. (ADBE) Q1 2024 Earnings Call Transcript Ulta Beauty, Inc. (ULTA) Q4 2023 Earnings Call Transcript Adobe Earnings: 3 Key Areas To Focus On With The Release Adobe in charts: Digital media revenue climbs ...
FDA Oncologic Drugs Advisory Committee voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat based on results from the IMerge Phase 3 clinical trial There are significant unmet needs across key TD LR-MDS patient populations, including difficult-to-treat subgroups that are ...
2024-03-14 15:39:52 ET More on Geron Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA Geron Corporation (GERN) Q4 2023 Earnings Call Transcript Geron's Ideal Situation Appears To Be Already Priced In Geron slips as FDA reviews blood ...
2024-03-12 11:00:48 ET More on Geron Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA Geron Corporation (GERN) Q4 2023 Earnings Call Transcript Geron's Ideal Situation Appears To Be Already Priced In Seeking Alpha’s Quant Rati...
News, Short Squeeze, Breakout and More Instantly...